Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02066103 · ClinicalTrials.gov registry record · NA
Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients
A NA study, sponsored by Mercator MedSystems.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT02066103: Completed NA study, sponsored by Mercator MedSystems.
NCT02066103 is a NA study that has completed, run by Mercator MedSystems. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02066103, a NA study, has completed, sponsored by Mercator MedSystems.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
Assess the safety and feasibility of local oncological drug delivery into the bronchial wall after recanalization of subjects with malignant airway obstruction. Safety and feasibility (technical success) will be assessed. This localized delivery is intended as an adjunct therapy and all subjects will receive standard of care oncology therapy as determined by their treating physicians.
Interventions
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-07 |
| Est. Completion | 2016-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02066103
The ClinicalTrials.gov registry entry for NCT02066103 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mercator MedSystems, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paclitaxel is the first listed.
NCT02066103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02066103 about?
NCT02066103 is a clinical study titled "Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients". Assess the safety and feasibility of local oncological drug delivery into the bronchial wall after recanalization of subjects with malignant airway obstruction. Safety and feasibility (technical success) will be assessed. This localized delivery is intended as an adjunct therapy and all subjects wi...
What is the current status of trial NCT02066103?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2014-07. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02066103?
The interventions under investigation include: Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02066103?
This trial is sponsored by Mercator MedSystems, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.